Anticoagulation and coagulation management for ECMO

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 3, 2009, Pages 154-175

  Oliver, William C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticoagulation; Extracorporeal circuit; Thromboelastogram; Thrombosis; Transfusion

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN; KAOLIN; PROTHROMBIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL OXYGENATION; HUMAN; INFLAMMATION; NEUROLOGICAL COMPLICATION; PARTIAL THROMBOPLASTIN TIME; REVIEW; THROMBOCYTE; THROMBOELASTOGRAPHY; THROMBOSIS;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD TRANSFUSION; CHILD; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; THROMBELASTOGRAPHY; THROMBOSIS;

EID: 70349305687     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253209347384     Document Type: Review

References (86)

1. Wolfson PJ The development and use of extracorporeal membrane oxygenation in neonates. Ann Thorac Surg. 2003 ; 76: S2224 - S2229.
2. Ayad O., Dietrich A., Mihalov L. Extracorporeal membrane oxygenation. Emerg Med Clin North Am. 2008 ; 26: 953-959.
3. Green TP, Payne NR, Steinhorn RH Determinants of blood product use during extracorporeal membrane oxygenation. Transfusion. 1990 ; 30: 289-290.
4. Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Undar A. Extracorporeal Life Support Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J. 2009 ; 55: 111-116.
5. Aird WC Coagulation. Crit Care Med. 2005 ; 33: S485 - S487.
6. Edmunds LH Jr, Colman RW Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006 ; 82: 2315-2322.
7. Roberts HR, Monroe DM, Escobar MA Current concepts of hemostasis: implications for therapy. Anesthesiology. 2004 ; 100: 722-730.
8. Butenas S., Orfeo T., Mann KG Tissue factor activity and function in blood coagulation. Thromb Res. 2008 ; 122 (suppl 1). S42 - S46.
9. Andrew M., Mitchell L., Vegh P., Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost. 1994 ; 72: 836-842.
10. Williams MD, Chalmers EA, Gibson BE ; Haemostasis, Thrombosis Task Force BCfSiH. The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol. 2002 ; 119: 295-309.
11. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the full-term infant. Blood. 1987 ; 70: 165-172.
12. Richardson MW, Allen GA, Monahan PE Thrombosis in children: current perspective and distinct challenges. Thromb Haemost. 2002 ; 88: 900-911.
13. Miller BE, Bailey JM, Mancuso TJ, et al. Functional maturity of the coagulation system in children: an evaluation using thrombelastography. Anesth Analg. 1997 ; 84: 745-748.
14. Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001 ; 72: S1821 - S1831.
15. Skinner SC, Hirschl RB, Bartlett RH Extracorporeal life support. Semin Pediatr Surg. 2006 ; 15: 242-250.
16. Fitch JC, Rollins S., Matis L., et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999 ; 100: 2499-2506.
17. Jaggers J., Lawson JH Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. Ann Thorac Surg. 2006 ; 81: S2360 - S2366.
18. Seghaye MC, Duchateau J., Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg. 1993 ; 106: 978-987.
19. Boldt J., Knothe C., Zickmann B., et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg. 1993 ; 105: 705-711.
20. Urlesberger B., Zobel G., Zenz W., et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr. 1996 ; 129: 264-268.
21. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999 ; 23: 979-983.
22. Fink SM, Bockman DE, Howell CG, Falls DG, Kanto WP Jr. Bypass circuits as the source of thromboemboli during extracorporeal membrane oxygenation. J Pediatr. 1989 ; 115: 621-624.
23. Rastan AJ, Lachmann N., Walther T., et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs. 2006 ; 29: 1121-1131.
24. Oliver WCJ. Overview of heparin and protamine management and dosing regimens in pediatric cardiac surgical patients. Semin Cardiothorac Vasc Anesth. 2003 ; 7: 387-410.
25. Bull BS, Huse WM, Brauer FS, Korpman RA Heparin therapy during extracorporeal circulation: II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975 ; 69: 685-689.
26. Young JA, Kisker CT, Doty DB Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978 ; 26: 231-240.
27. Baird CW, Zurakowski D., Robinson B., et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007 ; 83: 912-919.
28. Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996 ; 76: 902-908.
29. Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 1996 ; 10: 458-463.
30. Colby CE, Sheehan A., Benitz W., Van Meurs K., Halamek LP, Moss RL Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extra Corpor Technol. 2003 ; 35: 35-38.
31. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 ; 108: 1076-1082.
32. Chan AK, Leaker M., Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997 ; 77: 270-277. [Erratum appears in Thromb Haemost. 1997 ; 77: 1047 ]
33. Owings JT, Pollock ME, Gosselin RC, Ireland K., Jahr JS, Larkin EC Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg. 2000 ; 135: 1042-1047.
34. Guzzetta NA, Bajaj T., Fazlollah T., et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg. 2008 ; 106: 419-425.
35. Codispoti M., Mankad PS Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice. Perfusion. 2000 ; 15: 191-201.
36. Huyzen RJ, van Oeveren W., Wei F., Stellingwerf P., Boonstra PW, Gu YJ In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg. 1996 ; 62: 533-537.
37. Koster A., Despotis G., Gruendel M., et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2002 ; 95: 26-30.
38. Lawson DS, Walczak R., Lawson AF, et al. North American neonatal extracorporeal membrane oxygenation (ECMO) devices: 2002 survey results. J Extra Corpor Technol. 2004 ; 36: 16-21.
39. Paniccia R., Fedi S., Carbonetto F., et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. Anesthesiology. 2003 ; 99: 54-59.
40. Ganter MT, Hofer CK Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008 ; 106: 1366-1375.
41. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass. Anesth Analg. 2004 ; 99: 1290-1294.
42. Green TP, Isham-Schopf B., Irmiter RJ, Smith C., Uden DL, Steinhorn RH Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther. 1990 ; 48: 148-154.
43. Green TP, Isham-Schopf B., Steinhorn RH, Smith C., Irmiter RJ Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Crit Care Med. 1990 ; 18: 494-498.
44. Agati S., Ciccarello G., Salvo D., Turla G., Undar A., Mignosa C. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J. 2006 ; 52: 513-516.
45. Mallett SV, Cox DJ Thrombelastography. Br J Anaesth. 1992 ; 69: 307-313.
46. Spiess BD, Wall MH, Gillies BS, Fitch JC, SOltow LO, Chandler WL A comparison of thromboelastography with heparinase or protamine sulfate added in vitro during heparinized cardiopulmonary bypass. Thromb Haemost. 1997 ; 78: 820-826. [Erratum appears in Thromb Haemost. 1998 ; 80: 868 ]
47. Watson HG, Greaves M. Can we predict bleeding ? Semin Thromb Hemost. 2008 ; 34: 97-103.
48. O'Neill AI, McAllister C., Corke CF, Parkin JD A comparison of five devices for the bedside monitoring of heparin therapy. Anaesth Intensive Care. 1991 ; 19: 592-596.
49. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med. 2003 ; 29: 325-328 [Erratum appears in Intensive Care Med. 2003 ; 29: 664 ]
50. Hirsh J., Raschke R., Warkentin TE, Dalen JE, Deykin D., Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995 ; 108 (4 suppl). 258S - 275S.
51. Oliver WC Jr, Beynen FM, Nuttall GA, et al. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg. 2003 ; 75: 1506-1512.
52. Turner-Gomes SO, Nitschmann EP, Norman GR, Andrew ME, Williams WG Effect of heparin loading during congenital heart operation on thrombin generation and blood loss. Ann Thorac Surg. 1997 ; 63: 482-488.
53. Guzzetta NA, Miller BE, Todd K., Szlam F., Moore RH, Tosone SR An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg. 2005 ; 100: 1276-1282.
54. Dietrich W., Braun S., Spannagl M., Richter JA Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg. 2001 ; 92: 66-71.
55. Despotis GJ, Gravlee G., Filos K., Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999 ; 91: 1122-1151.
56. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001 ; 94: 773-781.
57. Nankervis CA, Preston TJ, Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J. 2007 ; 53: 111-114.
58. Arnold P., Jackson S., Wallis J., Smith J., Bolton D., Haynes S. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med. 2001 ; 27: 1395-1400.
59. Hashimoto K., Yamagishi M., Sasaki T., Nakano M., Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg. 1994 ; 58: 799-804.
60. Alsoufi B., Shen I., Karamlou T., et al. Extracorporeal life support in neonates, infants, and children after repair of congenital heart disease: modern era results in a single institution. Ann Thorac Surg. 2005 ; 80: 15-21.
61. McManus ML, Kevy SV, Bower LK, Hickey PR Coagulation factor deficiencies during initiation of extracorporeal membrane oxygenation. J Pediatr. 1995 ; 126: 900-904.
62. Kern FH, Morana NJ, Sears JJ, Hickey PR Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992 ; 54: 541-546.
63. Miller BE, Mochizuki T., Levy JH, et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg. 1997 ; 85: 1196-1202.
64. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Coagulation tests during cardiopulmonary bypass correlates with blood loss in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1999 ; 13: 398-404.
65. Miller BE, Guzzetta NA, Tosone SR, Levy JH Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. Anesth Analg. 2000 ; 90: 1324-1330.
66. Miller BE, Guzzetta NA, Tosone SR, et al. Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. Anesth Analg. 2003 ; 97: 1289-1293.
67. Chan K. -L, Summerhayes RG, Ignjatovic V., Horton SB, Monagle PT Reference values for kaolin-activated thromboelastography in healthy children. Anesth Analg. 2007 ; 105: 1610-1613.
68. Tuman KJ, McCarthy RJ, Djuric M., Rizzo V., IvankovichAD Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth. 1994 ; 8: 144-149.
69. Spalding GJ, Hartrumpf M., Sierig T., Oesberg N., Kirschke CG, Albes JM Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg. 2007 ; 31: 1052-1057.
70. Harker LA Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective α-granule release. Blood. 1980 ; 56: 824.
71. Mohr R., Golan M., Martinowitz U., Rossner E., Goor DA, Ramot B. Effect of cardiac operation on platelets. J Thorac Cardiovasc Surg. 1986 ; 92: 434-441.
72. Wenger RK, Lukasiewicz H., Mikuta BS, Niewiarowski S., Edmunds LH Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989 ; 97: 235-239.
73. Zilla P., Fasol R., Groscurth P., Klepetko W., Reichenspurner H., Wolner E. Blood platelets in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg. 1989 ; 97: 379-388.
74. Chang T. -T. Transfusion therapy in critically ill children. Pediatr Neonatol. 2008 ; 49: 5-12.
75. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007 ; 83 (5 suppl). S27 - S86.
76. Fries D., Krismer A., Klingler A., et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth. 2005 ; 95: 172-177.
77. Miller BE, Tosone SR, Guzzetta NA, Miller JL, Brosius KK Fibrinogen in children undergoing cardiac surgery: is it effective ? Anesth Analg. 2004 ; 99: 1341-1346.
78. Kallis P., Tooze JA, Talbot S., Cowans D., Bevan DH, Treasure T. Aprotinin inhibits fibrinolysis, improves platelet adhesion and reduces blood loss. Results of a double-blind randomized clinical trial. Eur J Cardiothorac Surg. 1994 ; 8: 315-322.
79. Hocker JR, Saving KL Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. J Pediatr Surg. 1995 ; 30: 1490-1492.
80. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002 ; 124: 852-854.
81. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007 ; 84: 161-168.
82. Ekert H., Brizard C., Eyers R., Cochrane A., Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis. 2006 ; 17: 389-395.
83. Veldman A., Neuhaeuser C., Akintuerk H., et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth. 2007 ; 17: 1176-1181.
84. Wittenstein B., Ng C., Ravn H., Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005 ; 6: 473-476.
85. Dominguez TE, Mitchell M., Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2005 ; 6: 348-351.
86. Swaminathan M., Shaw AD, Greenfield RA, Grichnik KP Fatal thrombosis after factor VII administration during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth. 2008 ; 22: 259-260.